Teva UK Limited Enters Wounds Sector With PolyHeal(TM) Launch

CASTLEFORD, England, November 15, 2010 - Teva UK Limited, a leading supplier of medicines to the NHS, has today
entered the Wound Care sector with the launch of PolyHeal (TM) at the Wounds
UK conference. PolyHeal is a product for hard-to-heal wounds and has been
clinically shown to result in a significant reduction in wound size after
just one month's treatment - even in wounds with exposed bones and tendons.

The product consists of negatively charged polystyrene microspheres,
suspended in a nutrient medium, which interact with cellular components
within the wound bed to activate the inflammatory and proliferation phases of
wound healing(1,2). It has clinically proven results in treating hard-to-heal
wounds across a variety of wound types(3):

    - Granulation coverage in 63% of wounds after four weeks
    - 40% wound size reduction after four weeks
    - 36% of wounds closed within 12 weeks

The results of two open-label studies of chronic wounds of multiple
aetiologies - including venous, diabetic and ischaemic ulcers - showed that
87% of patients treated with PolyHeal achieved significant wound improvement
after four weeks of treatment3. Furthermore, all exposed bones and tendons
were covered after four weeks3.

Speaking at the launch, Robyn Hughes, Primary & Secondary Care Director
at Teva, said: "We're delighted to bring this exciting new product to the UK
market and believe it will make a real difference to patients suffering from
hard-to-heal wounds." Marketing Manager, Dr Andrew Ellis, added: "There
remains an unmet need in the treatment of chronic wounds - we are confident
that PolyHeal will become a cornerstone of therapy in this challenging market
segment."

The product will be available from wholesalers in January 2011.

To find out more about Teva UK Limited, visit www.tevauk.com

    Notes to Editors:

    References:

    1) Dulbecco's Modified Eagle's Medium (DMEM)
    2) PolyHeal(TM) Instructions For Use
    3) Zeilig G. et al. Study to evaluate PolyHeal-1 in treatment of
       recalcitrant wounds. DOF November 2010

About Teva UK Limited

Teva UK Limited is one of the UK's top ten pharmaceutical manufacturers,
with a presence in the generics, branded respiratory and hospitals markets.
It has the widest range of any UK generic pharmaceutical company and markets
solid and liquid dose, injectable and respiratory medicines to healthcare
professionals. The company is part of Teva Pharmaceutical Industries Ltd.

About Teva Pharmaceutical Industries Ltd

Teva Pharmaceutical Industries Ltd. (NASDAQ: TEVA) is a leading global
pharmaceutical company, committed to increasing access to high-quality
healthcare by developing, producing and marketing affordable generic drugs as
well as innovative and specialty pharmaceuticals and active pharmaceutical
ingredients. Headquartered in Israel, Teva is the world's largest generic
drug maker, with a global product portfolio of more than 1,250 molecules and
a direct presence in 59 countries.

Teva's branded businesses focus on neurological, respiratory and women's
health therapeutic areas as well as biologics. Teva's leading innovative
product, Copaxone(R), is the number one prescribed treatment for multiple
sclerosis. Teva employs over 40,000 people around the world and reached $13.9
billion in net sales in 2009.

———————————

For media enquiries, contact the Teva UK Limited Communications team on
+44(0)1977-628500, or email media.enquiries@tevauk.com.

For media enquiries, contact the Teva UK Limited Communications team on +44(0)1977-628500, or email media.enquiries at tevauk.com.